UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
Leukemia, Lymphoma
About this trial
This is an interventional treatment trial for Leukemia focused on measuring Waldenström macroglobulinemia, refractory chronic lymphocytic leukemia, refractory hairy cell leukemia, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed recurrent or refractory low-grade or indolent lymphoid malignancies requiring systemic therapy, including the following: Grade I or II follicular small cleaved cell lymphoma Small lymphocytic lymphoma/leukemia subtypes (chronic lymphocytic leukemia) Mantle cell lymphoma Waldenstrom's macroglobulinemia Lymphoplasmacytoid Marginal zone (nodal, extranodal, or splenic subtypes) Hairy cell leukemia Transformed indolent subtypes allowed provided 1 of the following criteria are met: Previously treated with a doxorubicin-containing regimen No rapidly progressing disease that threatens vital functions Measurable disease No active leptomeningeal or parenchymal CNS lymphoma NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm^3 Platelet count at least 50,000/mm^3 No active Coomb's-positive hemolytic anemia Hepatic: Total bilirubin less than 2.0 mg/dL (unless elevation is due to Gilbert's disease and direct bilirubin is normal) Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: No angina No congestive heart failure No myocardial infarction within the past 6 months Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative No insulin-dependent diabetes mellitus PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics More than 3 weeks since prior systemic chemotherapy and recovered Endocrine therapy: More than 3 weeks since prior systemic steroid therapy and recovered Radiotherapy: Not specified Surgery: Not specified
Sites / Locations
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
- NCI - Center for Cancer Research